<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427661</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #0504048</org_study_id>
    <nct_id>NCT00427661</nct_id>
  </id_info>
  <brief_title>A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen</brief_title>
  <official_title>A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: A novel nonmyeloablative condition regimen will be safe and efficacious in&#xD;
      producing stable donor chimerism and cure of severe hemoglobinopathy.&#xD;
&#xD;
      Hypothesis 2: Stable donor chimerism will result in amelioration of cerebral vasculopathy,&#xD;
      improved cerebral perfusion and neurocognitive function.&#xD;
&#xD;
      Specific Aim 1: Study the safety and efficacy of a novel non-toxic conditioning regimen for&#xD;
      HSCT for patients with severe hemoglobinopathies and the kinetics of lineage specific&#xD;
      chimerism after HSCT&#xD;
&#xD;
      We will test our hypothesis that a novel nonmyeloablative condition regimen will be safe and&#xD;
      efficacious in producing stable donor chimerism and cure of severe hemoglobinopathy:&#xD;
&#xD;
      Specific Aim 2: Optimize the immunosuppressive regimen for HSCT patients through a thorough&#xD;
      understanding of the pharmacokinetics of Busulfan (BU) and mycophenolate mofetil (MMF) in the&#xD;
      patient population. This will involve:&#xD;
&#xD;
        1. Determine the pharmacokinetics of intravenously and orally administered MMF and&#xD;
           intravenous BU in patients receiving HSCT.&#xD;
&#xD;
        2. Determine the relationship of Area under the curve (AUC) of BU and mean trough&#xD;
           concentrations of mycophenolic acid (MPA) to engraftment and graft versus host disease&#xD;
           (GVHD).&#xD;
&#xD;
        3. Determine the relationship of Area under the curve (AUC) and steady state concentration&#xD;
           of BU to engraftment at day 30 and 1 year post HSCT.&#xD;
&#xD;
      Specific Aim 3: Study the effect of complete or partial donor chimerism on silent and overt&#xD;
      cerebral vasculopathy, and neurocognitive functioning in patients with SCD undergoing HSCT.&#xD;
      We will test our hypothesis that stable donor chimerism will result in improvement in&#xD;
      cerebral vasculopathy and neurocognitive function. This will include.&#xD;
&#xD;
        1. Determine effect of transplantation silent and overt cerebral vasculopathy by comparison&#xD;
           MRA and TCD 1 year after HSCT to pre-HSCT studies.&#xD;
&#xD;
        2. Determine effect on HSCT on neurocognitive function. Specific Aim 4: To determine the&#xD;
           rate of T cell immune reconstitution in children with sickle cell disease following&#xD;
           myeloablative compared to nonmyeloablative stem cell transplantation, using&#xD;
           immunophenotyping assays, CDR3 spectratyping TREC analysis, and measurement of T cell&#xD;
           specific donor engraftment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe hemoglobinopathies such as sickle cell disease (SCD) and Thalassemia are associated&#xD;
      with considerable morbidity, organ damage and premature mortality. Allogeneic hematopoietic&#xD;
      stem cell transplantation (HSCT) is the only therapy that can cure a hemoglobinopathy. The&#xD;
      applicability of HSCT for hemoglobinopathies is limited by the paucity of suitable donors,&#xD;
      and risk of early regimen-related toxicity and the late effects. Reduction of the dose of&#xD;
      myelotoxic drugs in preparative regimens prior to HSCT has the potential to increase the&#xD;
      applicability of this curative option for patients with hemoglobinopathies. We hypothesize&#xD;
      that a preparative regimen that maximizes host immunosuppression without myeloablation will&#xD;
      be well tolerated and sufficient for engraftment of donor hematopoietic stem cells in&#xD;
      patients with severe hemoglobinopathies. The long term objective of this research is to&#xD;
      develop novel, less toxic approaches to HSCT for patients with severe hemoglobinopathies.&#xD;
      Specific aims: 1. To evaluate the safety and efficacy of a novel nontoxic nonmyeloablative&#xD;
      approach to hematopoietic stem cell transplantation for hemoglobinopathies. 2. To optimize&#xD;
      the immunosuppressive regimen for HSCT patients through a thorough understanding of the&#xD;
      pharmacokinetics of Busulfan (BU) and Mycophenolic acid (MPA) 3. To determine the effect of&#xD;
      partial or complete donor chimerism on cerebral vasculopathy in patients with SCD. 4. To&#xD;
      determine the rate of T cell immune reconstitution in children with sickle cell disease&#xD;
      following myeloablative compared to nonmyeloablative stem cell transplantation, using&#xD;
      immunophenotyping assays, CDR3 spectratyping TREC analysis, and measurement of T cell&#xD;
      specific donor engraftment. Subjects meeting eligibility criteria in whom an human leukocyte&#xD;
      antigen matched, partially mismatched related or unrelated donor of bone marrow or umbilical&#xD;
      cord blood will receive a HSCT after a nonmyeloablative preparative regimen consisting of BU,&#xD;
      Fludarabine (FLU), total lymphoid radiation and Anti-Thymocyte globulin followed by&#xD;
      prophylaxis against graft versus host disease with cyclosporine A and MMF. Patients will be&#xD;
      studied for survival, cure of hemoglobinopathy, absence of severe regimen related toxicity&#xD;
      and graft versus host disease. The relationship of engraftment, survival and Graft versus&#xD;
      host disease to kinetics of lineage specific donor chimerism and area under the curve for&#xD;
      Mycophenolic acid and Busulfan will be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of GVHD Within 1 Year of BMT</measure>
    <time_frame>1 year</time_frame>
    <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment at 1 Year Post BMT.</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of total PBMC chimerism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 2-4 Acute GVHD.</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>Hemoglobinopathies</condition>
  <arm_group>
    <arm_group_label>AHCT in High Risk SCD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: Busulfan; Fludarabine; cyclosporine A and MMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Busulfan; Fludarabine; cyclosporine A and MMF</intervention_name>
    <description>Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen</description>
    <arm_group_label>AHCT in High Risk SCD</arm_group_label>
    <other_name>Busulfex, Fludara, Gengraf, CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with SCD 0-35 years of age with an HLA-identical or 1 HLA antigen mismatched&#xD;
             bone marrow or up to 2 HLA antigen mismatched umbilical cord blood (UCB) donor with&#xD;
             one or more of the following:&#xD;
&#xD;
               -  Stroke, CNS hemorrhage or a neurologic event lasting longer than 24 hours, or&#xD;
                  abnormal cerebral MRI or cerebral arteriogram or MRI angiographic study and&#xD;
                  impaired neuropsychological testing,&#xD;
&#xD;
               -  Acute chest syndrome with a history of recurrent hospitalizations or exchange&#xD;
                  transfusions,&#xD;
&#xD;
               -  Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more&#xD;
                  years or recurrent priapism,&#xD;
&#xD;
               -  Impaired neuropsychological function and abnormal cerebral MRI scan,&#xD;
&#xD;
               -  Stage I or II sickle lung disease,&#xD;
&#xD;
               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration&#xD;
                  rate [GFR] 30-50% of the predicted normal value),&#xD;
&#xD;
               -  Bilateral proliferative retinopathy and major visual impairment in at least one&#xD;
                  eye,&#xD;
&#xD;
               -  Osteonecrosis of multiple joints with documented destructive changes,&#xD;
&#xD;
               -  Requirement for chronic transfusions but with RBC alloimmunization &gt;2 antibodies&#xD;
                  during long term transfusion therapy.&#xD;
&#xD;
               -  Patients with transfusion dependent Thalassemia 0-35 years of age with an&#xD;
                  HLA-identical or 1 HLA antigen mismatched bone marrow or up to 2 HLA antigen&#xD;
                  mismatched UCB donor.&#xD;
&#xD;
          -  Second Transplants&#xD;
&#xD;
               -  Patients with sickle cell disease or Thalassemia who have failed to engraft or&#xD;
                  have autologous recovery are eligible for this protocol.&#xD;
&#xD;
               -  Patients must meet above criteria.&#xD;
&#xD;
               -  If first transplant was a non-myeloablative regimen, the second transplant can&#xD;
                  occur at any time.&#xD;
&#xD;
               -  If the first transplant was a myeloablative regimen, then the second transplant&#xD;
                  must be &gt; 6 months from the first transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with one or more of the following:&#xD;
&#xD;
               -  Karnofsky or Lansky performance score &lt;70,&#xD;
&#xD;
               -  Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on&#xD;
                  biopsy,&#xD;
&#xD;
               -  Stage III-IV lung disease,&#xD;
&#xD;
               -  GFR&lt;30% predicted normal values.&#xD;
&#xD;
               -  Pregnant or lactating females.&#xD;
&#xD;
          -  Active serious infection whereby patient has been on intravenous antibiotics for one&#xD;
             week prior to study entry. Any patient with AIDS or ARC or HIV seropositivity. Any&#xD;
             patient with invasive aspergillums infection within one year of study entry.&#xD;
&#xD;
          -  Psychologically incapable of undergoing BMT with associated strict isolation or&#xD;
             documented history of medical non-compliance.&#xD;
&#xD;
          -  Patients not able to receive TLI due to prior radiation therapy.&#xD;
&#xD;
        Donor Inclusion Criteria&#xD;
&#xD;
          -  Donor must be in good health based on review of systems and results of physical&#xD;
             examination.&#xD;
&#xD;
          -  Donor must have a normal hemoglobin, white count, platelet count and PTT.&#xD;
&#xD;
          -  Female donors of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
        Donor Exclusion Criteria&#xD;
&#xD;
          -  Donor has active infection (including HIV, hepatitis).&#xD;
&#xD;
          -  Donor is a lactating female.&#xD;
&#xD;
        Donor Selection&#xD;
&#xD;
        In the case where more than one donor meets the eligibility criteria, donor selection will&#xD;
        be guided by the following considerations:&#xD;
&#xD;
          -  HLA A, B, DRB1 identical sibling donor is preferable to an unrelated donor&#xD;
&#xD;
          -  Homozygous normal donor is preferable to heterozygote (carrier)&#xD;
&#xD;
          -  ABO-compatible donor is preferable to ABO-incompatible donor&#xD;
&#xD;
          -  Younger donor is preferable to older&#xD;
&#xD;
          -  Cytomegalovirus seronegative donor is preferable to CMV seropositive donor, if the&#xD;
             patient is CMV negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmanan Krishnamurti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>February 19, 2016</results_first_submitted>
  <results_first_submitted_qc>July 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2016</results_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Lakshmanan Krishnamurti</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of GVHD Within 1 Year of BMT</title>
        <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHSC in Severe SCD</title>
            <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of GVHD Within 1 Year of BMT</title>
          <description>GVHD is assessed by physical exam, bloodwork and biopsy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Engraftment at 1 Year Post BMT.</title>
        <description>Measurement of total PBMC chimerism</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHSC in Severe SCD</title>
            <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment at 1 Year Post BMT.</title>
          <description>Measurement of total PBMC chimerism</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 2-4 Acute GVHD.</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Busulfan, Fludarabine, Cyclosporine, MMF</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 2-4 Acute GVHD.</title>
          <units>participants with grade 2-4 AGVHD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AHSC in Severe SCD</title>
          <description>The patient population for this study included severe SCD patients, both pediatric and adult, who did not have end-organ failure, and met all of the eligibility criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Arterial Hypertension</sub_title>
                <description>21 year old female patient developed complications related to sickle cell disease associated progressive pulmonary arterial hypertension and died 10 months post BMT.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Mild pancreatitis Day +109&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Poor oral intake</sub_title>
                <description>Required transient parenteral alimentation&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Line related bacteremia</sub_title>
                <description>line related bacteremia with Rhizobium radiobactor d100&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Dermatomal herpes zoster Parainfluenza A infection&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Line related bacteremia</sub_title>
                <description>Line related bacteremia d244&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizure day+11 secondary to low level of phenytoin&#xD;
(Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>headache day +1-+4, post transplant, requiring analgesics (Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <description>Hemoglobinuria immediately following stem cell transplant the resolved within 48 hours (Krishnamurti et al., 2008. Biol Blood Marrow Transplant 14:1270)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Harter-Administrative Director of Research</name_or_title>
      <organization>University of Pittsburgh-Department of Pediatrics</organization>
      <phone>412-692-7487</phone>
      <email>harterne@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

